Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7725MR)

This product GTTS-WQ7725MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7725MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12071MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ2383MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ7585MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ14628MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ13261MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ15034MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ10779MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ14579MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW